These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 304740)

  • 1. Characteristics of various factor VIII concentrates used in treatment of haemophilia A.
    Nilsson IM; Hedner U
    Br J Haematol; 1977 Dec; 37(4):543-57. PubMed ID: 304740
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease.
    Tuddenham EG; Lane RS; Rotblat F; Johnson AJ; Snape TJ; Middleton S; Kernoff PB
    Br J Haematol; 1982 Oct; 52(2):259-67. PubMed ID: 6812613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific factor VIII-related antigen fragmentation: an in vivo and in vitro phenomenon.
    Montgomery RR; Johnson J
    Blood; 1982 Oct; 60(4):930-9. PubMed ID: 6180785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor VIII:C and VIII:CAg response in patients with haemophilia A and von Willebrand's disease after administration of different factor VIII concentrates or plasma.
    Holmberg L; Borge L; Nilsson IM
    Br J Haematol; 1981 Apr; 47(4):587-96. PubMed ID: 6783063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunologic studies in von Willebrand's disease: alteration of factor VIII/von Willebrand protein after transfusion with plasma concentrates in patients with von Willebrand's disease.
    Sultan Y; Simeon J; Maisonneuve P; Caen JP
    Thromb Haemost; 1976 Feb; 35(1):110-9. PubMed ID: 1085498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of hepatitis A after treatment with pasteurised factor VIII concentrates in children with haemophilia A and von Willebrand disease.
    Kreuz W; Klarmann D; Auerswald G; Auberger K; Gürtler L; Rabenau H; Doerr WD
    Lancet; 1993 Feb; 341(8842):446. PubMed ID: 8094219
    [No Abstract]   [Full Text] [Related]  

  • 7. Factor VIII-related antigen (VIII R:AG) in haemophilic patients and in carriers.
    Bowie EJ; Fass DN
    Lancet; 1979 Nov; 2(8151):1049-50. PubMed ID: 91786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concentrated preparations of Factor 8 (antihaemophilic globulin) in the management of haemophilia A and von Willebrand's disease.
    Castaldi PA; Somer JB; Schiff P; Blackburn CR
    Med J Aust; 1967 Sep; 2(11):481-5. PubMed ID: 5299300
    [No Abstract]   [Full Text] [Related]  

  • 9. Progress in the clinical management of haemophilia.
    Bloom AL
    Thromb Haemost; 1991 Jul; 66(1):166-77. PubMed ID: 1926047
    [No Abstract]   [Full Text] [Related]  

  • 10. DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease.
    Warrier AI; Lusher JM
    J Pediatr; 1983 Feb; 102(2):228-33. PubMed ID: 6401806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood and neoplastic diseases. Haemophilia and related disorders.
    Rizza CR
    Br Med J; 1974 Oct; 4(5935):36-8. PubMed ID: 4547674
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatitis C and pasteurised factor VIII and IX concentrates.
    Klarmann D; Kreuz W; Auerswald G; Auberger K; Rabenau H; Gürtler L; Roggendorf M
    Thromb Haemost; 1995 Apr; 73(4):736-7. PubMed ID: 7495095
    [No Abstract]   [Full Text] [Related]  

  • 13. Haemophilia in children. Current immunologic status of a pediatric population.
    Carnelli V; Giulotto P; Magnolfi C; Cordini M; Simoni L; Cultrera S; Bardare M
    Scand J Haematol Suppl; 1984; 40():359-65. PubMed ID: 6433462
    [No Abstract]   [Full Text] [Related]  

  • 14. [Hemophilia and related diseases, with special reference to therapeutic policy].
    Nagao T
    Nihon Rinsho; 1974 May; 32(5):993-9. PubMed ID: 4603576
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment protocol of haemophilia and other congenital bleeding disorders in Italy. Italian Association of Hemophilia Centers (AICE).
    Gringeri A
    Haemophilia; 1998 Jul; 4(4):423-4. PubMed ID: 9873767
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibitor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates.
    Goudemand J
    Haemophilia; 2007 Dec; 13 Suppl 5():47-51. PubMed ID: 18078397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous inheritance and expression of classical haemophilia A and type IIA von Willebrand's disease.
    Beddall AC; Enayat SM; Williams CE; Short PE; Hill FG
    J Clin Pathol; 1984 Sep; 37(9):1035-9. PubMed ID: 6432854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A.
    Bidlingmaier C; Kurnik K; Escuriola-Ettingshausen C; Jager R; Klamroth R; Male C; Marosi A; Nemes L; von Stackelberg A; Kreuz W
    Haemophilia; 2011 Sep; 17(5):e837-40. PubMed ID: 21649797
    [No Abstract]   [Full Text] [Related]  

  • 19. Cryoprecipitate therapy in haemophilia.
    Forbes CD; Hunter J; Barr RD; Davidson JF; Short DW; McDonald GA; McNicol GP; Wallace J; Douglas AS
    Scott Med J; 1969 Jan; 14(1):1-9. PubMed ID: 5304824
    [No Abstract]   [Full Text] [Related]  

  • 20. Continuous infusion therapy in haemophilia.
    Varon D; Martinowitz U
    Haemophilia; 1998 Jul; 4(4):431-5. PubMed ID: 9873771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.